181 related articles for article (PubMed ID: 37773553)
21. Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis.
Li S; Hsu DD; Wang H; Feng GS
Front Med; 2012 Sep; 6(3):275-9. PubMed ID: 22869052
[TBL] [Abstract][Full Text] [Related]
22. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S
Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822
[TBL] [Abstract][Full Text] [Related]
23. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
Prahallad A; Heynen GJ; Germano G; Willems SM; Evers B; Vecchione L; Gambino V; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Bernards R
Cell Rep; 2015 Sep; 12(12):1978-85. PubMed ID: 26365186
[TBL] [Abstract][Full Text] [Related]
24. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576
[TBL] [Abstract][Full Text] [Related]
25. Noonan syndrome patients beyond the obvious phenotype: A potential unfavorable metabolic profile.
Noronha RM; Villares SMF; Torres N; Quedas EPS; Homma TK; Albuquerque EVA; Moraes MB; Funari MFA; Bertola DR; Jorge AAL; Malaquias AC
Am J Med Genet A; 2021 Mar; 185(3):774-780. PubMed ID: 33382187
[TBL] [Abstract][Full Text] [Related]
26. PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism.
Dai W; Xiang W; Han L; Yuan Z; Wang R; Ma Y; Yang Y; Cai S; Xu Y; Mo S; Li Q; Cai G
Cancer Commun (Lond); 2022 Sep; 42(9):848-867. PubMed ID: 35904817
[TBL] [Abstract][Full Text] [Related]
27. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
28. Critical roles of PTPN family members regulated by non-coding RNAs in tumorigenesis and immunotherapy.
Tang X; Qi C; Zhou H; Liu Y
Front Oncol; 2022; 12():972906. PubMed ID: 35957898
[TBL] [Abstract][Full Text] [Related]
29. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
Stasik S; Eckardt JN; Kramer M; Röllig C; Krämer A; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause S; Herbst R; Hänel M; Frickhofen N; Noppeney R; Kaiser U; Baldus CD; Kaufmann M; Rácil Z; Platzbecker U; Berdel WE; Mayer J; Serve H; Müller-Tidow C; Ehninger G; Bornhäuser M; Schetelig J; Middeke JM; Thiede C;
Blood Adv; 2021 Sep; 5(17):3279-3289. PubMed ID: 34459887
[TBL] [Abstract][Full Text] [Related]
30. Ether lipid and sphingolipid expression patterns are estrogen receptor-dependently altered in breast cancer cells.
Hahnefeld L; Gruber L; Schömel N; Fischer C; Mattjus P; Gurke R; Beretta M; Ferreirós N; Geisslinger G; Wegner MS
Int J Biochem Cell Biol; 2020 Oct; 127():105834. PubMed ID: 32827762
[TBL] [Abstract][Full Text] [Related]
31. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
32. The role of Shp2 (PTPN11) in cancer.
Mohi MG; Neel BG
Curr Opin Genet Dev; 2007 Feb; 17(1):23-30. PubMed ID: 17227708
[TBL] [Abstract][Full Text] [Related]
33. miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC).
Kikkawa N; Hanazawa T; Fujimura L; Nohata N; Suzuki H; Chazono H; Sakurai D; Horiguchi S; Okamoto Y; Seki N
Br J Cancer; 2010 Sep; 103(6):877-84. PubMed ID: 20700123
[TBL] [Abstract][Full Text] [Related]
34. Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo.
Ardini E; Agresti R; Tagliabue E; Greco M; Aiello P; Yang LT; Ménard S; Sap J
Oncogene; 2000 Oct; 19(43):4979-87. PubMed ID: 11042685
[TBL] [Abstract][Full Text] [Related]
35. Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase.
Zhang S; Fan G; Hao Y; Hammell M; Wilkinson JE; Tonks NK
Genes Dev; 2017 Oct; 31(19):1939-1957. PubMed ID: 29066500
[TBL] [Abstract][Full Text] [Related]
36. Integrative genome wide analysis of protein tyrosine phosphatases identifies CDC25C as prognostic and predictive marker for chemoresistance in breast cancer.
Topno R; Nazam N; Kumari P; Kumar M; Agarwal P
Cancer Biomark; 2021; 32(4):491-504. PubMed ID: 34275890
[TBL] [Abstract][Full Text] [Related]
37. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.
Jongmans MC; van der Burgt I; Hoogerbrugge PM; Noordam K; Yntema HG; Nillesen WM; Kuiper RP; Ligtenberg MJ; van Kessel AG; van Krieken JH; Kiemeney LA; Hoogerbrugge N
Eur J Hum Genet; 2011 Aug; 19(8):870-4. PubMed ID: 21407260
[TBL] [Abstract][Full Text] [Related]
38. Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
Xu D; Zheng H; Yu WM; Qu CK
PLoS One; 2013; 8(5):e63152. PubMed ID: 23675459
[TBL] [Abstract][Full Text] [Related]
39. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.
Yuan T; Wang Y; Zhao ZJ; Gu H
J Biol Chem; 2010 May; 285(20):14861-14870. PubMed ID: 20335174
[TBL] [Abstract][Full Text] [Related]
40. PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort.
Otani R; Ikegami M; Yamada R; Yajima H; Kawamura S; Shimizu S; Tanaka S; Takayanagi S; Takami H; Yamaguchi T
J Neurooncol; 2023 Aug; 164(1):221-229. PubMed ID: 37552362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
